Skip to main content
SpringerLink
Log in

Bupropion for smoking cessation

A review

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

Smoking tobacco is the leading cause of preventable death. Bupropion is the only antidepressant recommended as first-line pharmacotherapy for smoking cessation. Bupropion is as effective as nicotine replacement therapy and can be used in diverse populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention. Average annual number of deaths, 1995–1999, MMWR 2002; 51 (14): 300–303.

    Google Scholar 

  2. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Rockville, MD: Public Health Service; June 2000.

    Google Scholar 

  3. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanisms of antidepressant activity. J Clin Psychiatry 1995; 56 (9): 395–401.

    PubMed  CAS  Google Scholar 

  4. Clarke PB. Nicotine dependence—mechanisms and therapeutic strategies. Biochem Soc Symp 1993; 59: 83–95.

    PubMed  CAS  Google Scholar 

  5. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295 (1): 321–327.

    PubMed  CAS  Google Scholar 

  6. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288 (1): 88–92.

    PubMed  CAS  Google Scholar 

  7. Shiffman S., Johnston JA, Khayrallah M, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 2000; 148 (1): 33–40.

    Article  CAS  Google Scholar 

  8. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 2003; 168 (3): 347–358.

    Article  CAS  Google Scholar 

  9. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release burpropion and placebo for smoking cessation. N Engl J Med 1997; 337 (17): 1195–1202.

    Article  PubMed  CAS  Google Scholar 

  10. Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003; 163 (19): 2337–2344.

    Article  PubMed  CAS  Google Scholar 

  11. Hughes J, Sted L., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004 (4): CD000031.

    PubMed  Google Scholar 

  12. Ferry LH, Robbins A, Scariati P, et al. Enhancement of smoking cessation using the antideperessant bupropion hydrochloride. Circulation 1992; 86 (4 Suppl 1): I-671.

    Google Scholar 

  13. Ferry LH, Burchette R. Efficacy of bupropion for smoking cessation in non depressed smokers. J Addictive Diseases 1994; 13 (4): 249.

    Google Scholar 

  14. Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001; 69 (6): 438–444.

    Article  PubMed  CAS  Google Scholar 

  15. Hall SM, Humflett GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59 (10): 930–936.

    Article  PubMed  CAS  Google Scholar 

  16. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340 (9): 685–691.

    Article  PubMed  CAS  Google Scholar 

  17. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357 (9268): 1571–1575.

    Article  PubMed  CAS  Google Scholar 

  18. Tonnesen P, Tonstad S, Hjalmarson A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003; 254 (2): 184–192.

    Article  PubMed  CAS  Google Scholar 

  19. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24 (10): 946–955.

    Article  PubMed  CAS  Google Scholar 

  20. Zellweger JP, Boeleskei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ, Bupropion SR vs placebo for smoking cessation in health care professionals. Am J Health Behav 2005; 29 (3): 240–249.

    PubMed  Google Scholar 

  21. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 2002; 288 (4): 468–474.

    Article  PubMed  CAS  Google Scholar 

  22. Collins BN, Wileyto EP, Patterson F, et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res 2004; 6 (1): 27–37.

    Article  PubMed  CAS  Google Scholar 

  23. Dalsgareth OJ, Hansen NC, Soes-Petersen U, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res 2004; 6 (1): 55–61.

    Article  PubMed  CAS  Google Scholar 

  24. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001; 3 (4): 397–403

    Article  PubMed  CAS  Google Scholar 

  25. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebocontrolled trial of bupropions sustained-release for smoking cessation in schizophrenai. J Clin Psychopharmacol 2005; 25 (3): 218–225.

    Article  PubMed  CAS  Google Scholar 

  26. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002; 52 (1): 53–61.

    Article  PubMed  CAS  Google Scholar 

  27. Hetzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychoparmacol 2001; 21 (1): 94–98.

    Article  Google Scholar 

  28. Piper M, Federman E, Smith S, Fiore M, Baker T. Efficacy of bupropion SR alone and combined with 4-mg gum (abstract). Society for Research on Nicotine and Tobacco 10th Annual Meeting, Phoenix, AZ. February 18–21 2004.

  29. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 2004; 99 (9): 1206–1218.

    Article  PubMed  CAS  Google Scholar 

  30. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. Arch Intern Med 2004; 164 (16): 1797–1803.

    Article  PubMed  CAS  Google Scholar 

  31. Killen JD, Robinson TN, Ammerman S, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 2004; 72 (4): 729–735.

    Article  PubMed  Google Scholar 

  32. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation, a randomized, controlled trial. Ann Intern Med 2001; 135 (6): 423–433.

    PubMed  CAS  Google Scholar 

  33. Hurt RD, Krook JE, Croghan IT, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol 2003; 21 (5): 914–920.

    Article  PubMed  CAS  Google Scholar 

  34. Durcan MJ, White J, Jorenby DE, et al. Impact of prior nicotine replacement therapy on smoking cesation efficacy. Am J Health Behav 2002; 26 (3): 213–220.

    PubMed  Google Scholar 

  35. Hatsukami DK, Rennard S, Patel MK, et al. Effects of sustatined-release bupropion among persons interested in reducing but not quitting smoking. Am J Med 2004; 116 (3): 151–157.

    Article  PubMed  CAS  Google Scholar 

  36. Holt S, Timu-Parata C, Ryder-Lewis S, Weatherall M, Beasley R. Efficacy of bupropions in the indigenous Maori population in New Zealand. Thorax 2005; 60 (2): 120–123.

    Article  PubMed  CAS  Google Scholar 

  37. Covey LS, Glassman AH, Stener F, Becker J, Effect of history of alcoholism or major depression on smoking cessation. Am J Psychiatry 1993; 150 (10): 1546, 1547.

    PubMed  CAS  Google Scholar 

  38. Tsoh JY, Humfleet GL, Munoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry 2000; 157 (3): 368–374.

    Article  PubMed  CAS  Google Scholar 

  39. Glassman AH, Covey LS, Stener F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001; 357 (9272): 1929–1932.

    Article  PubMed  CAS  Google Scholar 

  40. Hayford KE, Patten CA, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174: 173–178.

    Article  PubMed  CAS  Google Scholar 

  41. Cox LS, Patten CA, Niaura RS, et al. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 2004; 19 (8): 828–834.

    Article  PubMed  Google Scholar 

  42. GlaxoSmithKline. Zyban (bupropion hydrochloride) Sustained-Release Tablets. Product Information. Available at: http://us.gsk.com/products/assets/us_zyban.pdf. Accessed September 15, 2005.

Download references

Author information

Authors and Affiliations

  1. Division of General Internal Medicine and Center for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, CA

    Elisa K. Tong

  2. Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, CA

    Timothy P. Carmody

  3. Department of Psychiatry, University of California, San Francisco, San Francisco, CA

    Timothy P. Carmody

  4. General Internal Medicine Section, San Francisco Veterans Affairs Medical Center, San Francisco, CA

    Joel A. Simon MM, MPH

  5. Department of Medicine and Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

    Joel A. Simon MM, MPH

Authors
  1. Elisa K. Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy P. Carmody
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joel A. Simon MM, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel A. Simon MM, MPH.

Additional information

The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors do not discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products or devices.

About this article

Cite this article

Tong, E.K., Carmody, T.P. & Simon, J.A. Bupropion for smoking cessation. Compr Ther 32, 26–33 (2006). https://doi.org/10.1385/COMP:32:1:26

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/COMP:32:1:26

Keywords

Search

Navigation